**Table 2**. Novel published agents in FL in the last years

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **New Agent** | **Classification** | **Reference** | **Cases** | **ORR** | **CR** | **PFS/TTP$** |
| *Ibritumomab Tiuxetan* | Radio-conjugated MoAb& | Witzig et al. 200256 | 54 | 74% | 15% | Median 6.8moths |
| *Ofatumumab* | MoAb anti-CD20 | Czuczman, et al, 201263 | 116 | 10-13% | 0% | Median 5.8 moths |
| *Ibrutinib* | BTK inhibitor | Advani et al. 201258 | 16 | 37% | 18.5% | Median 13.6 months\* |
| *Obinotuzumab* | MoAb anti-CD20 | Sehn et al. 201465 | 74 | 44.6% | 12.2% | 45.8% at 2 year |
| *Idelalisb#* | PI3Kδ inhibitor | Gopal et al, 201460 | 72 | 57% | 6% | Median 11 months |
| *R-Pidilizumab* | anti-PD MoAb | Westin et al. 201462 | 32 | 66% | 52% | Median 18.8 months |
| *Lenalidomide* | Immunomodulatory | Leonard et al, 201561 | 45 | 53.3% | 20% | 27% at 2 year |
| *R-Lenalidomide* | Immunomodulatory | Leonard et al, 201562 | 46 | 76.1% | 39.1% | 52% at 2 year |
| *Polatuzumab+* | Anti-CD79b drug conjugate MoAb | Palanca-Wessels et al, 201566 | 16 | 43% | 18.5% | Median 7.9 moths |

$ PFS= progression free survival/ TTP = time to progression

& MoAb = monoclonal antibody

\*considering all lymphoma enrolled in the study

# indolent lymphoma of whom 58% FL

+data related to indolent lymphoma study arm